Unexpected shakeup at Akcea comes amid drug launches

Akcea Therapeutics lost roughly $412 million in market cap as the executive team was unexpectedly gutted on Monday. For now, an interim CEO hailing from majority owner Ionis Pharmaceuticals has been installed. The shakeup could have a negative effect on the biotech as it’s in the midst of two new drug launches.


Read the full 522 word article

How to gain access

Continue reading with a
two-week free trial.